Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
- Late-Breaking Phase 3 Data from the IDEAL Study Highlight the Impact of Livdelzi® on Composite Alkaline Phosphatase Gilead Sciences, Inc. will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management across these rare and serious liver diseases. Gilead's scientific program includes 21 accepted abstracts, including late-breaking Phase 3 research from the Livdelzi® (seladelpar) 10 mg development program and new long-time evidence for Hepcludex® (bulevirtide-gmod) 2 mg and 8.5 mg in chronic HDV. Additional data on safety and efficacy of seladelpar up to five years and late-break data on fatigue will also be presented. As treatment options evolve, Gileads' ambitions for people living with rare liver diseases should also evolve.
Được phát hành : 6 giờ trước qua Business Wire trong Health Science
Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® ... [20095 symbols]
Chủ đề: Data
